Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07334119Phase 1Recruiting

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Role: lead

NCT06478693Phase 1Recruiting

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Role: lead

NCT05969041Phase 1Recruiting

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Role: lead

NCT05138458Phase 1Suspended

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Role: lead

All 4 trials loaded